Guangzhou Regenex Pharmaceutical

Guangzhou Regenex Pharmaceutical is a clinical-stage biotechnology company based in Guangzhou, China, focused on developing innovative small molecule therapies for respiratory and inflammatory diseases. As the pharmaceutical development arm of RayBiotech, the company leverages advanced protein-based discovery platforms to identify novel therapeutic targets. Its lead candidate, R-107, is a proprietary nitric oxide donor prodrug currently in Phase 2 clinical development for the treatment of pulmonary arterial hypertension and COVID-19-related lung injury. Regenex also explores the application of its nitric oxide technology in treating chemical-induced lung injuries, such as those caused by chlorine gas. The company aims to address critical unmet needs in vascular and pulmonary medicine through its specialized pipeline of nitric oxide-based therapeutics.